% | $
Quotes you view appear here for quick access.

Dyax Corp. (DYAX) Message Board

  • carvedolol carvedolol Dec 13, 2012 11:39 PM Flag

    Lilly Statement on IMC-1121B

    I don't mean to be repetitious--but for those who don't realize what IMC-1121B involves (made/co-licensed via DYAX technology), here's an except from Lilly:

    'Ramucirumab [IMC-1121B] represents one of the largest clinical programs currently underway at Lilly. Six global Phase III trials — one each in breast, colorectal, hepatocellular and lung cancer, and two in gastric cancer — are ongoing and patient enrollment milestones have recently been achieved in both the Phase III breast and gastric (monotherapy) cancer trials.'

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • In a report published Wednesday, January 9, 2013, Bank of America Merrill Lynch reiterated its Buy rating on Eli Lilly & Co. (NYSE: LLY), and raised its price target from $57.00 to $60.00.

      BofA Merrill Lynch noted, “...Several promising late-stage pipeline assets are underappreciated, in our view, and could be transformative to LLYs growth trajectory (ramucirumab, solanezumab and the four Phase III diabetes assets - two basal insulins, empagliflozin and dulaglutide).”

38.410.00(0.00%)Jan 21 4:00 PMEST